A multidisciplinary management approach to cervical cancer during pregnancy

Nobody puts "cancer diagnosis" on their pregnancy bingo card. Swollen ankles? Sure. Weird cravings at 2 AM? Expected. But a cervical cancer diagnosis at 10 weeks pregnant? That's the kind of plot twist nobody signed up for - and yet it happens to roughly 1.6 to 11.1 out of every 100,000 pregnant women worldwide.

A new case report in The Lancet by LeJeune and colleagues walks us through exactly this scenario: a 39-year-old woman, pregnant with her third child, who showed up at the emergency department with vaginal bleeding just past 10 weeks of gestation. What she got wasn't just a diagnosis - it was a masterclass in how modern medicine juggles two patients in one body.

When Your Body Is Building a Human and a Tumor Simultaneously

Cervical cancer is the fourth most common cancer in women globally, with about 660,000 new cases estimated in 2022 alone. It ranks among the top three cancers for women under 45 in nearly 80% of countries assessed. Almost all cases trace back to persistent infection with human papillomavirus - HPV 16 and 18 are the main troublemakers, responsible for about 70% of cases. The good news: screening catches it early. The complicated news: pregnancy can mask symptoms and make every treatment decision feel like a chess game played on a tightrope.

Here's the thing about finding cancer during pregnancy - pregnant patients actually tend to present with earlier-stage disease compared to non-pregnant women. Only about 26% of pregnant patients are diagnosed at stage II-IV, versus 52% in non-pregnant women. Probably because pregnancy comes with a lot of medical attention and someone eventually takes a closer look at that bleeding.

The Art of Treating Cancer Without Evicting the Tenant

The team at University Hospitals Leuven - led by senior author Frédéric Amant, who literally founded the International Network on Cancer, Infertility and Pregnancy (INCIP) back in 2005 - put their patient on a weekly regimen of paclitaxel and carboplatin. This isn't as reckless as it sounds. Chemotherapy is a no-go during the first trimester (the fetus is building all its major organs, and chemo drugs are not great construction consultants), but from the second trimester onward - after about 14 weeks - platinum-based chemotherapy paired with taxanes has shown response rates between 66% and 85%.

Why carboplatin over cisplatin? Cisplatin carries a risk of ototoxicity in the newborn - basically, it can mess with baby's hearing. Carboplatin is the gentler cousin at the family reunion. The dose was adjusted as needed; when thrombocytopenia (low platelets) showed up around week 21, they paused, waited for recovery, and resumed with a reduced dose. This is medicine as improvisation - responding to what the body throws at you, cycle by cycle.

It Takes a Village (of Specialists)

The paper's title says "multidisciplinary" and it means it. We're talking gynecologic oncologists, obstetricians, neonatologists, radiologists, medical oncologists, and probably someone whose entire job is making sure these people are all in the same room at the same time. The 2025 ESGO/INCIP guidelines now formally recommend this team-based approach for all gynecological cancers during pregnancy, covering everything from imaging and pathology to psychological support.

And the data backs it up. INCIP's registry - spanning 67 hospitals across 28 countries - shows that 88% of registered cases resulted in live births. Yes, 47% delivered preterm, and neonatal complications like leukopenia (3%) and neutropenia (7%) do occur. But congenital malformation rates? About 3%, which is the same as the general population. Brain imaging studies of chemotherapy-exposed infants show no significant differences in regional or total brain volumes compared to unexposed controls.

Cesarean Section: Not Optional

One detail worth highlighting: vaginal delivery after cervical cancer is essentially off the table. Among 27 women who delivered vaginally in one review, nine developed recurrence at the episiotomy site. Nine out of 27. That's a recurrence rate that would make any oncologist break into a cold sweat. Cesarean delivery is the clear standard.

The Bigger Picture

Twenty years ago, a cancer diagnosis during pregnancy often meant an impossible choice: your life or the pregnancy. Today, thanks to networks like INCIP and work from teams like Amant's, the evidence increasingly shows that cancer can be treated during pregnancy without jeopardizing maternal survival or fetal development. It's not simple - every case is a high-wire act of dose adjustments, imaging decisions, and delivery timing. But it is possible, and getting better.

The real takeaway from this Lancet paper isn't just one patient's story. It's proof that when you assemble the right team and follow the evidence, you don't have to choose between two lives. You fight for both.

References:

1. LeJeune CL, Van Calsteren K, Baert T, Vandecaveye V, Amant F. A multidisciplinary management approach to cervical cancer during pregnancy. The Lancet. 2026. DOI: 10.1016/S0140-6736(26)00190-X

2. Le Guévelou J, Selleret L, Laas E, Lecuru F, Kissel M. Cervical cancer associated with pregnancy: current challenges and future strategies. Cancers (Basel). 2024;16(7):1341. DOI: 10.3390/cancers16071341. PMCID: PMC11011172.

3. Maggen C, Wolters VERA, Cardonick E, et al. Pregnancy and cancer: the INCIP project. Current Oncology Reports. 2020;22(2):17. DOI: 10.1007/s11912-020-0862-7. PMCID: PMC7002463.

4. ESGO/INCIP Guidelines for the management of patients with gynecological cancers during pregnancy. International Journal of Gynecological Cancer. 2025. Available at: IJGC

5. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health. 2020;8(2):e191-e203. DOI: 10.1016/S2214-109X(19)30482-6. PMCID: PMC7025157.

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.